- Abstract:
-
Background:
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This study evaluated the efficacy and safety of tofacitinib 5 mg twice daily monotherapy after methotrexate withdrawal.
Methods:
Expand abstract
OPAL Balance was an open-label, long-term extension study of tofacitinib in patients with psoriatic arthritis who participated in the OPAL Broaden and OPAL Bey... - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Rheumatology Journal website
- Publication date:
- 2020-11-16
- Acceptance date:
- 2020-08-24
- DOI:
- EISSN:
-
2665-9913
- Pubs id:
-
1133215
- Local pid:
- pubs:1133215
- Language:
- English
- Keywords:
- Copyright holder:
- Elsevier
- Rights statement:
- © 2020 Elsevier Ltd. All rights reserved.
Journal article
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record